Inovio, like Moderna, is conducting a Phase 1 human trial of its vaccine, with 40 volunteers enrolled. It plans to report initial results on safety and...
Early data show that Inovio Pharmaceuticals’ experimental vaccine triggered immune responses against the Covid-19 virus in lab animals.
The study results published Wednesday in the science journal Nature lifted Inovio stock 8.2% to $15.76 near midday—echoing the enthusiasm that swept up shares of rival Moderna on Monday, when that company released an encouraging bit of data on the first eight Americans vaccinated in a Phase 1 clinical trial. That enthusiasm had a short half-life.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Be Careful Handling White-Hot Moderna StockInvestors were celebrating after hopeful news around a potential coronavirus vaccine. Spencerjakab explains why they should still be cautious. WSJWhatsNow
Read more »
Early data on Moderna's COVID-19 vaccine insufficient: Stat NewsData from a small, early-stage safety trial testing Moderna Inc's experimental COVID-19 vaccine does not provide critical data to assess its effectiveness, Stat News reported on Tuesday, citing experts.
Read more »
Early data on Moderna's COVID-19 vaccine insufficient: Stat NewsData from a small, early-stage safety trial testing Moderna Inc's experimental COVID-19 vaccine does not provide the critical data needed to assess its effectiveness, health-focused Stat News reported on Tuesday, citing experts.
Read more »
Dow spikes 912 points as vaccine progress spurs economic-reopening optimism | Markets InsiderUS stocks surged on Monday as Moderna announced that its coronavirus vaccine candidate had shown encouraging progress. In a small number of heal...
Read more »
Asian stocks rise after Moderna's coronavirus vaccine delivers early positive results | Markets InsiderAsian stocks rose on Tuesday after Moderna reported promising results from the first human trials of its coronavirus vaccine. US futures slid af...
Read more »
Vaccine experts say Moderna didn't produce data critical to assessing Covid-19 vaccineHeavy hearts soared Monday with news that Moderna's Covid-19 vaccine candidate — the frontrunner in the American market — seemed to be generating an immune response in Phase 1 trial subjects.
Read more »